Why is Trump wooing psychedelics? It's really about Iran

Key Points:

• President Donald Trump signed an executive order to expedite federal review of psychedelic drugs for mental illness treatment, signaling increased government attention on substances like LSD and psilocybin despite their illegal status.
• The order, supported by Health and Human Services Secretary Robert F. Kennedy Jr. and witnessed by podcaster Joe Rogan, aims to accelerate FDA drug approval processes and DEA rescheduling timelines, potentially shortening approval by several months.
• Experts and industry insiders are divided; some view the order as largely symbolic or politically motivated amid Trump's Iran war, while others see it as a meaningful shift toward legitimizing psychedelic therapies.
• The executive order includes $50 million in funding for psychedelic therapy research, though details on allocation remain unclear; proponents highlight growing bipartisan support and less opposition compared to cannabis rescheduling efforts.
• While the order may not drastically change drug approval timelines, it marks unprecedented White House backing for psychedelic medicine, potentially influencing future drug policy and mainstream acceptance.